- Home
- CGEN vs ELDN Comparison
CGEN vs ELDN Comparison
Compare CGEN & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGEN
- ELDN
- Stock Information
- Founded
- CGEN 1993
- ELDN 2004
- Country
- CGEN Israel
- ELDN United States
- Employees
- CGEN N/A
- ELDN N/A
- Industry
- CGEN Biotechnology: Biological Products (No Diagnostic Substances)
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- CGEN Health Care
- ELDN Health Care
- Exchange
- CGEN Nasdaq
- ELDN Nasdaq
- Market Cap
- CGEN 167.4M
- ELDN 178.4M
- IPO Year
- CGEN 2000
- ELDN N/A
- Fundamental
- Price
- CGEN $1.73
- ELDN $2.79
- Analyst Decision
- CGEN
- ELDN Strong Buy
- Analyst Count
- CGEN 0
- ELDN 2
- Target Price
- CGEN N/A
- ELDN $12.50
- AVG Volume (30 Days)
- CGEN 265.3K
- ELDN 618.2K
- Earning Date
- CGEN 08-05-2025
- ELDN 08-18-2025
- Dividend Yield
- CGEN N/A
- ELDN N/A
- EPS Growth
- CGEN N/A
- ELDN N/A
- EPS
- CGEN N/A
- ELDN N/A
- Revenue
- CGEN $27,589,000.00
- ELDN N/A
- Revenue This Year
- CGEN N/A
- ELDN N/A
- Revenue Next Year
- CGEN $173.80
- ELDN N/A
- P/E Ratio
- CGEN N/A
- ELDN N/A
- Revenue Growth
- CGEN N/A
- ELDN N/A
- 52 Week Low
- CGEN $1.13
- ELDN $2.30
- 52 Week High
- CGEN $2.66
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- CGEN 57.84
- ELDN 45.10
- Support Level
- CGEN $1.62
- ELDN $2.60
- Resistance Level
- CGEN $1.81
- ELDN $2.91
- Average True Range (ATR)
- CGEN 0.08
- ELDN 0.17
- MACD
- CGEN -0.00
- ELDN -0.00
- Stochastic Oscillator
- CGEN 65.22
- ELDN 36.54
About CGEN Compugen Ltd.
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.